ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER
| dc.contributor.author | Tillyashaikhov M. N | |
| dc.contributor.author | Khakimov G. A | |
| dc.contributor.author | Abdurakhimov O. N | |
| dc.contributor.author | Malikov M. A | |
| dc.date.accessioned | 2025-12-29T12:46:12Z | |
| dc.date.issued | 2024-06-10 | |
| dc.description.abstract | The introduction of tyrosine kinase inhibitors into clinical practice has significantly improved treatment outcomes for patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). Lenvatinib is recommended as a first-line drug for this category of patients | |
| dc.format | application/pdf | |
| dc.identifier.uri | https://westerneuropeanstudies.com/index.php/3/article/view/1131 | |
| dc.identifier.uri | https://asianeducationindex.com/handle/123456789/19458 | |
| dc.language.iso | eng | |
| dc.publisher | Western European Studies | |
| dc.relation | https://westerneuropeanstudies.com/index.php/3/article/view/1131/747 | |
| dc.rights | https://creativecommons.org/licenses/by-nc/4.0 | |
| dc.source | Western European Journal of Medicine and Medical Science; Vol. 2 No. 6 (2024): WEJMMS; 11-20 | |
| dc.source | 2942-1918 | |
| dc.subject | To analyze the aggregated clinical | |
| dc.subject | lenvatinib | |
| dc.subject | radioiodine-refractory thyroid cancer | |
| dc.subject | clinical practice | |
| dc.title | ЭFFICACY AND TOLERABILITY OF LENVATINIB IN RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | Peer-reviewed Article |
item.page.files
item.page.filesection.original.bundle
pagination.showing.detail
loading.default
- item.page.filesection.name
- n_2024_fficacy_and_tolerability_of_lenvatinib_i.pdf
- item.page.filesection.size
- 275.03 KB
- item.page.filesection.format
- Adobe Portable Document Format